Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 7;12(3):290.
doi: 10.3390/v12030290.

Purinergic Receptors: Elucidating the Role of these Immune Mediators in HIV-1 Fusion

Tracey L Freeman  1 , Talia H Swartz  1
Affiliations
Review

Purinergic Receptors: Elucidating the Role of these Immune Mediators in HIV-1 Fusion

Tracey L Freeman et al. Viruses. .

Abstract

Purinergic receptors are inflammatory mediators activated by extracellular nucleotides released by dying or injured cells. Several studies have described an important role for these receptors in HIV-1 entry, particularly regarding their activity on HIV-1 viral membrane fusion. Several reports identify purinergic receptor antagonists that inhibit HIV-1 membrane fusion; these drugs are suspected to act through antagonizing Env-chemokine receptor interactions. They also appear to abrogate activity of downstream mediators that potentiate activation of the NLRP3 inflammasome pathway. Here we review the literature on purinergic receptors, the drugs that inhibit their function, and the evidence implicating these receptors in HIV-1 entry.

Keywords: HIV-1; fusion; inflammation; purinergic.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Yoshimura K. Current status of HIV/AIDS in the ART era. J. Infect. Chemother. 2017;23:12–16. doi: 10.1016/j.jiac.2016.10.002. - DOI - PubMed
    1. Spitsin S., Tebas P., Barrett J.S., Pappa V., Kim D., Taylor D., Evans D.L., Douglas S.D. Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults. Jci Insight. 2017;2 doi: 10.1172/jci.insight.95893. - DOI - PMC - PubMed
    1. Schouten J., Wit F.W., Stolte I.G., Kootstra N.A., van der Valk M., Geerlings S.E., Prins M., Reiss P., Group A.G.C.S. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: The AGEhIV cohort study. Clin. Infect. Dis. 2014;59:1787–1797. doi: 10.1093/cid/ciu701. - DOI - PubMed
    1. O'Brien M.P., Hunt P.W., Kitch D.W., Klingman K., Stein J.H., Funderburg N.T., Berger J.S., Tebas P., Clagett B., Moisi D., et al. A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy. Open Forum Infect. Dis. 2017;4:ofw278. doi: 10.1093/ofid/ofw278. - DOI - PMC - PubMed
    1. Marchetti G., Tincati C., Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin. Microbiol Rev. 2013;26:2–18. doi: 10.1128/CMR.00050-12. - DOI - PMC - PubMed

Publication types

MeSH terms